Uncategorized
Baseline characteristics help predict visual acuity outcomes after anti-VEGF treatment for wet AMD
Lower best corrected visual acuity, younger age and smaller total area of choroidal neovascularization at baseline may be significant predictors for visual acuity outcomes when treating wet age-related macular degeneration patients with ranibizumab, according to a study.The retrospective analysis of the phase 3 HARBOR study evaluated demographic and baseline characteristics predictive to visual acuity outcomes in patients with subfoveal wet AMD. Over 12 months, 249 patients were treated with 0.5 mg of Lucentis (ranibizumab, Genentech) monthly and 251 patients were treated with the same dose on an as-needed basis after (Read more...)